Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE 2 production and prostaglandin related cachexia

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 99-107

  Wang, W ^a   Andersson, M ^a   Lonnroth C ^a   Svanberg, E ^a   Lundholm, K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anorexia; Cachexia; Cancer; EP receptor

Indexed keywords

INDOMETACIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN EP1 RECEPTOR; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; PROSTAGLANDIN EP4 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; BODY COMPOSITION; CACHEXIA; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH; WEIGHT REDUCTION; WILD TYPE;

ANIMAL FEED; ANIMALS; ANOREXIA; AUTOPSY; CACHEXIA; DINOPROSTONE; FATS; FEMALE; GENE DELETION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, PROSTAGLANDIN E;

EID: 18544379574     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lawson D.H., Richmond A., Nixon D.W. and Rudman D.: Metabolic approaches to cancer cachexia. Annu. Rev. Nutr. 2: 277-301, 1982.
2. Nelson K.A., Walsh D. and Sheehan F.A.: The cancer anorexia-cachexia syndrome. J. Clin. Oncol. 12: 213-225, 1994.
3. Puccio M. and Nathanson L.: The cancer cachexia syndrome. Semin. Oncol. 24: 277-287, 1997.
4. Tisdale MJ.: Biology of cachexia [see comments]. J. Natl. Cancer Inst. 89: 1763-1773, 1997.
5. Tisdale M.: Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 13: 1-7, 1997.
6. Cahlin C., Korner A., Axelsson H., Wang W., Lundholm K., and Svanberg E.: Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Res. 60: 5488-5493, 2000.
7. Cahlin C., Gelin J., Delbro D., Lonnroth C., Doi C. and Lundholm K.: Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res. 60: 1742-1749, 2000.
8. Lundholm K., Gelin J., Hyltander A., Lonnroth C., Sandstrom R., Svaninger G., Korner U., Gulich M., Karrefors I., Norli B. et al.: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54: 5602-5606, 1994.
9. 2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur. J. Neurosci. 11: 2651-2668, 1999.
10. 3 prostaglandin E(2) receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J. Comp. Neurol. 428: 5-20, 2000.
11. Wang W., Lönnroth C., Svanberg E. and Lundholm K.: Cytokine and cyclooxygenase-2 protein in brain areas of tumor-bearing mice with prostanoid-related anorexia. Cancer Research 61: 4707-4715, 2001.
12. Wang W, Andersson M., Lönnroth C., Svanberg E. and Lundholm K.: Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice. A model with prostanoid related cachexia. Int. J. Cancer Febr. 9, 2005.
13. Ushikubi F., Segi E., Sugimoto Y., Murata T., Matsuoka T., Kobayashi T., Hizaki H., Tuboi K., Katsuyama M., Ichikawa A., Tanaka T., Yoshida N., and Narumiya S.: Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281-284, 1998.
14. Lundholm K., Edstrom S., Ekman L., Karlberg I., Bylund A.C. and Schersten T.: A comparative study of the influence of malignant tumor on host metabolism in mice and man: evaluation of an experimental model. Cancer 42: 453-461, 1978.
15. Lönnroth C., Gelin J., and Lundholm K.: Expression of interleukin-6 in tumor-bearing mice with cytokine dependent cachexia. Int. J. Oncol. 5: 329-336, 1994.
16. Lönnroth C., Svaninger G., Gelin J., Cahlin C., Iresjö B.-M., Cvetkovska E., Edström S., Andersson M., Svanberg E. and Lundholm K.: Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int. J. Oncol. 7: 1405-1413, 1995.
17. Eden E., Lindmark L., Karlberg I. and Lundholm K.: Role of whole-body lipids and nitrogen as limiting factors for survival in tumor-bearing mice with anorexia and cachexia. Cancer Res. 43: 3707-3711, 1983.
18. 1 prostanoid receptor and the PKN protein kinase overlap. Biochem. Biophys. Res. Commun. 227: 70-76, 1996.
19. Coleman R.A., Smith W.L. and Narumiya S.: International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46; 205-229, 1994.
20. Narumiya S., Sugimoto Y. and Ushikubi F.: Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226, 1999.
21. Sugimoto Y., Narumiya S. and Ichikawa A.: Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 39: 289-314, 2000.
22. 3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol. 48: 869-879, 1995.
23. Watanabe M., Sakurai M., Abe K., Aoki M., Sadahiro M., Tabayashi K., Okamoto K., Shoji M. and Itoyama Y.: Inductions of Cu/Zn superoxide dismutase- and nitric oxide synthase-like immunoreactivities in rabbit spinal cord after transient ischemia. Brain Res. 732: 69-74, 1996.
24. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T. and Wakabayashi K.: Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62: 28-32, 2002.
25. 3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197: 221-232, 2003.
26. Eguchi N., Hayashi H., Urade Y., Ito S. and Hayaishi O.: Central action of prostaglandin E2 and its methyl ester in the induction of hyperthermia after their systemic administration in urethane-anesthetized rats. J. Pharmacol. Exp. Ther. 247: 671-679, 1988.
27. Laflamme N. and Rivest S.: Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. J. Neurochem. 73: 309-321, 1999.
28. Lacroix S., Vallieres L., and Rivest S.: C-fos mRNA pattern and corticotropin-releasing factor neuronal activity throughout the brain of rats injected centrally with a prostaglandin of E2 type. J. Neuroimmunol. 70: 163-179, 1996.
29. Scammell T.E., Elmquist J.K., Griffin J.D., and Saper C.B.: Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. J. Neurosci. 16: 6246-6254, 1996.
30. Takafuji V.A., Evans A., Lynch K.R. and Roche J.K.: PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins Leukot. Essent. Fatty Acids 66: 71-81, 2002.
31. Richelsen B.: Interaction of indomethacin with the antilipolytic effect of prostaglandin E2 in rat adipocytes. Mol. Cell. Endocrinol. 58: 85-91, 1988.
32. Richelsen B.: Release and effects of prostaglandins in adipose tissue. Prostaglandins Leukot. Essent. Fatty Acids 47: 171-182, 1992.
33. Axelrod L. and Levine L.: Plasma prostaglandin levels in rats with diabetes mellitus and diabetic ketoacidosis. Diabetes 31: 994-1001, 1982.
34. Vassaux G., Gaillard D., Darimont C., Ailhaud G. and Negrel R.: Differential response of preadipocytes and adipocytes to prostacyclin and prostaglandin E2: physiological implications. Endocrinology 131: 2393-2398, 1992.
35. Vassaux G., Gaillard D., Ailhaud G., and Negrel R.: Prostacyclin is a specific effector of adipose cell differentiation. Its dual role as a cAMP- and Ca(2+)-elevating agent. J. Biol. Chem. 267: 11092-11097, 1992.
36. 2 alpha. Biochim. Biophys. Acta 1091: 364-369, 1991.
37. Borglum J.D., Pedersen S.B., Ailhaud G., Negrel R. and Richelsen B.: Differential expression of prostaglandin receptor mRNAs during adipose cell differentiation. Prostaglandins Other Lipid Mediat. 57: 305-317, 1999.
38. Coleman R.A., Grix S.P., Head S.A., Louttit J.B., Mallett A. and Sheldrick R.L.: A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47: 151-168, 1994.
39. 4 subtype. FEBS Lett: 364: 339-341, 1995.
40. Lundholm K., Karlberg I., Ekman L., Edstrom S., and Schersten T.: Evaluation of anorexia as the cause of altered protein synthesis in skeletal muscles from nongrowing mice with sarcoma. Cancer Res. 41: 1989-1996, 1981.
41. Karlberg I., Edstrom S., Ekman L., Johansson S., Schersten T. and Lundholm K.: Metabolic host reaction in response to the proliferation of nonmalignant cells versus malignant cells in vivo. Cancer Res. 41: 4154-4161, 1981.